Information For the User Tolvaptan (30mg) Tablet

Tolvise 30 Tablet

Brand Name: Tolvise 30 Tablet

Dosage Form: Tablet

Composition:

• Tolvaptan I.P. 30 mg

Therapeutic Segment:

Nephrology / Fluid Management Segment

Therapeutic Indication:

Tolvise 30 Tablet is indicated for the **management of fluid retention and low sodium levels** (**hyponatremia**) associated with:

- Heart failure
- Cirrhosis of the liver
- Syndrome of inappropriate antidiuretic hormone secretion (SIADH)

It helps in reducing water retention, correcting serum sodium imbalance, and improving overall fluid status.

Mechanism of Action:

- Tolvaptan is a selective vasopressin V2 receptor antagonist.
- It increases excretion of free water (aquaresis) without significant loss of electrolytes, thereby raising serum sodium and reducing fluid overload.

Dosage & Administration:

- Take as directed by the physician, usually once daily in the morning.
- Swallow the tablet **whole with water**, with or without food.
- Regular monitoring of **serum sodium and kidney function** is recommended during therapy.

Contraindications:

- Hypersensitivity to **Tolvaptan**
- Anuria (absence of urine output)
- **Hypernatremia** (high serum sodium levels)

Warnings & Precautions:

- Monitor **serum sodium levels** to avoid rapid correction.
- Use with caution in patients with **liver impairment**.

• Avoid co-administration with strong CYP3A inhibitors.

Possible Side Effects:

- Thirst, dry mouth
- Increased urination
- Nausea, dizziness
- Rare: liver enzyme elevation, hypotension

Storage:

Store in a **cool**, **dry place below 25°C**, protected from light and moisture.

Segment:

Nephrology / Fluid Management Segment - It helps in managing fluid overload and hyponatremia, maintaining electrolyte balance, and supporting cardiovascular and renal health.

Manufactured in India for:



Cafoli Lifecare Pvt. Ltd.

(An ISO 9001: 2015 Certified Co.) Plot no.: 367-FF, Industrial Area Phase-I,

Panchkula-134113

TM: Trademark Applied for